Taylor Hoffman Wealth Management lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 24.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,380 shares of the company’s stock after buying an additional 3,000 shares during the quarter. Taylor Hoffman Wealth Management’s holdings in Merck & Co., Inc. were worth $1,295,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Titan Capital Management LLC CA bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA raised its stake in Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the last quarter. JJJ Advisors Inc. purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $27,000. Cumberland Partners Ltd purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $40,000. Finally, Fusion Family Wealth LLC raised its stake in Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the last quarter. 74.95% of the stock is owned by institutional investors.
Several equities research analysts have weighed in on MRK shares. Mizuho increased their price target on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Argus upped their target price on shares of Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Svb Leerink began coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They issued an “outperform” rating and a $103.00 target price for the company. Finally, Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $95.13.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.27. The company had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 earnings per share. Analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.